Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 13.14
(8.17%)
USD 13.14
(8.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 765.55 Million USD | 10.64% |
| 2022 | 691.93 Million USD | -2.56% |
| 2021 | 710.14 Million USD | 35.91% |
| 2020 | 522.5 Million USD | 49.35% |
| 2019 | 349.84 Million USD | 213.45% |
| 2018 | 111.6 Million USD | 7.29% |
| 2017 | 104.02 Million USD | -18.84% |
| 2016 | 128.17 Million USD | -3.09% |
| 2015 | 132.26 Million USD | -27.65% |
| 2014 | 182.81 Million USD | 389.74% |
| 2013 | 37.32 Million USD | 125.86% |
| 2012 | 16.52 Million USD | 4.02% |
| 2011 | 15.88 Million USD | 28.61% |
| 2010 | 12.35 Million USD | 60.4% |
| 2009 | 7.7 Million USD | -55.36% |
| 2008 | 17.25 Million USD | -42.2% |
| 2007 | 29.85 Million USD | -13.53% |
| 2006 | 34.52 Million USD | 18.89% |
| 2005 | 29.04 Million USD | 143.72% |
| 2004 | 11.91 Million USD | 686.03% |
| 2003 | 1.51 Million USD | 2285.01% |
| 2002 | 63.56 Thousand USD | 37.27% |
| 2001 | 46.3 Thousand USD | -28.92% |
| 2000 | 65.14 Thousand USD | -20.83% |
| 1999 | 82.29 Thousand USD | -2.94% |
| 1998 | 84.78 Thousand USD | -21.26% |
| 1997 | 107.67 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 883.75 Million USD | -7.47% |
| 2024 Q1 | 626.28 Million USD | -18.19% |
| 2024 Q2 | 955.15 Million USD | 52.51% |
| 2023 Q3 | 795.85 Million USD | -10.71% |
| 2023 Q2 | 891.3 Million USD | -0.02% |
| 2023 FY | 765.55 Million USD | 10.64% |
| 2023 Q1 | 891.48 Million USD | 28.84% |
| 2023 Q4 | 765.55 Million USD | -3.81% |
| 2022 Q1 | 638.53 Million USD | -10.08% |
| 2022 FY | 691.93 Million USD | -2.56% |
| 2022 Q4 | 691.93 Million USD | -7.96% |
| 2022 Q3 | 751.78 Million USD | 6.85% |
| 2022 Q2 | 703.57 Million USD | 10.19% |
| 2021 Q3 | 734.92 Million USD | -2.89% |
| 2021 Q4 | 710.14 Million USD | -3.37% |
| 2021 Q2 | 756.79 Million USD | 51.59% |
| 2021 FY | 710.14 Million USD | 35.91% |
| 2021 Q1 | 499.25 Million USD | -4.45% |
| 2020 Q3 | 555.72 Million USD | -0.95% |
| 2020 FY | 522.5 Million USD | 49.35% |
| 2020 Q1 | 587.6 Million USD | 67.96% |
| 2020 Q2 | 561.07 Million USD | -4.51% |
| 2020 Q4 | 522.5 Million USD | -5.98% |
| 2019 Q3 | 336.82 Million USD | 0.86% |
| 2019 Q4 | 349.84 Million USD | 3.86% |
| 2019 Q1 | 340.94 Million USD | 205.48% |
| 2019 FY | 349.84 Million USD | 213.45% |
| 2019 Q2 | 333.94 Million USD | -2.06% |
| 2018 Q2 | 126.99 Million USD | 43.96% |
| 2018 FY | 111.6 Million USD | 7.29% |
| 2018 Q3 | 112.9 Million USD | -11.1% |
| 2018 Q4 | 111.6 Million USD | -1.15% |
| 2018 Q1 | 88.22 Million USD | -15.19% |
| 2017 Q4 | 104.02 Million USD | -9.61% |
| 2017 FY | 104.02 Million USD | -18.84% |
| 2017 Q3 | 115.08 Million USD | -9.29% |
| 2017 Q2 | 126.87 Million USD | -12.05% |
| 2017 Q1 | 144.25 Million USD | 12.55% |
| 2016 Q2 | 94.6 Million USD | -15.06% |
| 2016 FY | 128.17 Million USD | -3.09% |
| 2016 Q4 | 128.17 Million USD | 49.86% |
| 2016 Q1 | 111.38 Million USD | -15.79% |
| 2016 Q3 | 85.53 Million USD | -9.59% |
| 2015 Q3 | 145.19 Million USD | -10.59% |
| 2015 FY | 132.26 Million USD | -27.65% |
| 2015 Q1 | 162.13 Million USD | -11.31% |
| 2015 Q4 | 132.26 Million USD | -8.9% |
| 2015 Q2 | 162.37 Million USD | 0.15% |
| 2014 Q3 | 196.62 Million USD | -2.97% |
| 2014 Q4 | 182.81 Million USD | -7.02% |
| 2014 FY | 182.81 Million USD | 389.74% |
| 2014 Q1 | 92.69 Million USD | 148.31% |
| 2014 Q2 | 202.64 Million USD | 118.62% |
| 2013 FY | 37.32 Million USD | 125.86% |
| 2013 Q1 | 15.23 Million USD | -7.85% |
| 2013 Q3 | 41.48 Million USD | 234.06% |
| 2013 Q4 | 37.32 Million USD | -10.02% |
| 2013 Q2 | 12.41 Million USD | -18.46% |
| 2012 FY | 16.52 Million USD | 4.02% |
| 2012 Q3 | 16.48 Million USD | -17.89% |
| 2012 Q1 | 23.06 Million USD | 45.15% |
| 2012 Q4 | 16.52 Million USD | 0.24% |
| 2012 Q2 | 20.08 Million USD | -12.93% |
| 2011 Q2 | 15.23 Million USD | 0.31% |
| 2011 Q4 | 15.88 Million USD | 19.55% |
| 2011 FY | 15.88 Million USD | 28.61% |
| 2011 Q1 | 15.18 Million USD | 22.95% |
| 2011 Q3 | 13.28 Million USD | -12.78% |
| 2010 Q1 | 9.12 Million USD | 18.53% |
| 2010 FY | 12.35 Million USD | 60.4% |
| 2010 Q4 | 12.35 Million USD | -15.36% |
| 2010 Q3 | 14.59 Million USD | 88.14% |
| 2010 Q2 | 7.75 Million USD | -15.02% |
| 2009 Q4 | 7.7 Million USD | -6.06% |
| 2009 Q3 | 8.19 Million USD | -19.37% |
| 2009 Q1 | 15.39 Million USD | -10.81% |
| 2009 FY | 7.7 Million USD | -55.36% |
| 2009 Q2 | 10.16 Million USD | -33.93% |
| 2008 Q1 | 30.66 Million USD | 2.72% |
| 2008 Q2 | 24.82 Million USD | -19.05% |
| 2008 Q3 | 19.12 Million USD | -22.95% |
| 2008 Q4 | 17.25 Million USD | -9.78% |
| 2008 FY | 17.25 Million USD | -42.2% |
| 2007 Q1 | 34.39 Million USD | -0.38% |
| 2007 Q3 | 36.71 Million USD | 36.47% |
| 2007 Q4 | 29.85 Million USD | -18.69% |
| 2007 FY | 29.85 Million USD | -13.53% |
| 2007 Q2 | 26.9 Million USD | -21.78% |
| 2006 FY | 34.52 Million USD | 18.89% |
| 2006 Q1 | 25.88 Million USD | -10.88% |
| 2006 Q4 | 34.52 Million USD | -14.92% |
| 2006 Q3 | 40.58 Million USD | -9.99% |
| 2006 Q2 | 45.08 Million USD | 74.21% |
| 2005 Q1 | 10.02 Million USD | -15.89% |
| 2005 FY | 29.04 Million USD | 143.72% |
| 2005 Q4 | 29.04 Million USD | -5.43% |
| 2005 Q3 | 30.7 Million USD | 110.93% |
| 2005 Q2 | 14.55 Million USD | 45.26% |
| 2004 Q1 | 2.12 Million USD | 40.35% |
| 2004 Q3 | 12.14 Million USD | 5.55% |
| 2004 FY | 11.91 Million USD | 686.03% |
| 2004 Q4 | 11.91 Million USD | -1.91% |
| 2004 Q2 | 11.5 Million USD | 440.92% |
| 2003 Q4 | 1.51 Million USD | 3187.44% |
| 2003 FY | 1.51 Million USD | 2285.01% |
| 2003 Q1 | 47.75 Thousand USD | -24.88% |
| 2003 Q2 | 43.28 Thousand USD | -9.36% |
| 2003 Q3 | 46.11 Thousand USD | 6.54% |
| 2002 FY | 63.56 Thousand USD | 37.27% |
| 2002 Q4 | 63.56 Thousand USD | -39.52% |
| 2002 Q2 | 50.07 Thousand USD | 3.02% |
| 2002 Q1 | 48.6 Thousand USD | 4.97% |
| 2002 Q3 | 105.08 Thousand USD | 109.86% |
| 2001 FY | 46.3 Thousand USD | -28.92% |
| 2001 Q1 | 61.69 Thousand USD | -5.31% |
| 2001 Q2 | 58.28 Thousand USD | -5.52% |
| 2001 Q4 | 46.3 Thousand USD | -20.14% |
| 2001 Q3 | 57.98 Thousand USD | -0.52% |
| 2000 Q3 | 66.65 Thousand USD | -3.99% |
| 2000 Q4 | 65.14 Thousand USD | -2.25% |
| 2000 FY | 65.14 Thousand USD | -20.83% |
| 2000 Q2 | 69.42 Thousand USD | -1.61% |
| 2000 Q1 | 70.56 Thousand USD | -29.44% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q4 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1999 FY | 82.29 Thousand USD | -2.94% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q4 | 100 Thousand USD | 0.0% |
| 1998 FY | 84.78 Thousand USD | -21.26% |
| 1997 FY | 107.67 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -124.635% |
| Codexis, Inc. | 136.56 Million USD | -460.593% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -56.1% |
| Organovo Holdings, Inc. | 6.34 Million USD | -11957.836% |